News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Dylan Galaty, Hay Group

Advertisement

Articles by Dylan Galaty, Hay Group

Salesforce Survey 2008

ByBob Davenport, Hay Group,Dylan Galaty, Hay Group,Carrie Fisher, Hay Group
January 1st 2008

Welcome to the new employer's market for reps. The Hay Group's annual survey reports how, as the primary sales force contracts, so too does its pay.

Advertisement

Latest Updated Articles

  • Salesforce Survey 2008
    Salesforce Survey 2008

    January 1st 2008



Advertisement
Advertisement

Trending on PharmExec

1

Vinay Prasad Out at CBER for Second Time in Under a Year

2

Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial

3

Mergers and Acquisitions Roundup: GSK and Alfasigma Enter Licensing Agreement for Linerixibat, Servier Enters $2.5 Billion Definitive Agreement to Acquire Day One Pharmaceuticals

4

Novo Nordisk Signs Deal with Hims & Hers

5

AI has Redefined Healthcare Communication — and There’s No Opting Out

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us